A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.
What Are The Drugs Involved
The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.
The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.
These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.
What Could This Mean For Bowel Cancer Treatment In The Future
The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.
All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.
Credit: iStock
Several antibiotics used to treat infections caused by E. coli and Klebsiella pneumoniae—bacteria linked to pneumonia, urinary tract and bloodstream infections—are showing low susceptibility in India, with resistance also reported to powerful drugs such as carbapenems, according to a new Indian Council of Medical Research (ICMR) report.
The newly released ICMR Antimicrobial Resistance Surveillance and Research Network (AMRSN) Annual Report 2025 assesses the distribution of bacterial pathogens and their susceptibility to different antibiotics.
The surveillance covers Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa, as well as Gram-positive bacteria such as Staphylococcus aureus and Enterococcus species.
For the first time, the report included data from 34 secondary-care hospitals, highlighting that antibiotic resistance is a concern beyond large, specialised hospitals.
The findings underscore the need for better diagnostics, responsible antibiotic use and stronger infection prevention.
"Antibiotic resistance is no longer a distant threat—it is affecting patients and families across India," Dr Neha Rastogi Panda, Senior Consultant, Infectious Diseases, Fortis Hospital, Gurugram, told HealthandMe.
Also read: Antimicrobial Resistance Could Contribute To 39 Million Deaths By 2050: WHO
The report highlighted several concerning resistance patterns across bacterial pathogens, including:
1. E. coli: Low susceptibility to cefotaxime and ceftazidime
The report showed that susceptibility of E. coli isolates to third-generation cephalosporins was low, with only 18.4% and 24.7% susceptible to cefotaxime and ceftazidime, respectively.
Low susceptibility was also observed among isolates from outpatient department (OPD) patients, suggesting that resistance to these antibiotics is widespread in the community and indicating a high prevalence of antibiotic-blocking enzymes.
2. K. pneumoniae: Low susceptibility to piperacillin-tazobactam and carbapenems
K. pneumoniae showed an alarmingly high resistance profile, with only 29.2% susceptible to piperacillin-tazobactam, 23–27% to third-generation cephalosporins, and only 35–40% to carbapenems.
Amikacin susceptibility was limited to 44.5%, while susceptibility to ceftazidime-avibactam was 37.7%. Tigecycline showed higher susceptibility, at 79.3%.
3. E. coli: Ceftriaxone susceptibility falls in secondary-care hospitals
Ceftriaxone susceptibility declined from 39.8% in Category I to 28.0% in Category II and 11.5% in Category III hospitals, indicating a high prevalence of resistance to third-generation cephalosporins even in smaller hospitals.
Meropenem susceptibility also declined across the three categories, from 80.3% to 77.5% and 67.1%, respectively.
4. Acinetobacter baumannii: High carbapenem resistance
A high prevalence of carbapenem resistance was observed among A. baumannii, with 91.1% of revived isolates exhibiting carbapenem resistance, highlighting a substantial therapeutic and infection-control challenge.
OXA-23 was the predominant carbapenemase determinant, with frequent detection of OXA-23 and NDM co-profiles.
5. Salmonella Typhi and Salmonella Paratyphi A: Very low ciprofloxacin susceptibility
Fluoroquinolone susceptibility was lowest among the antibiotics assessed for both pathogens. Ciprofloxacin susceptibility was observed in only 2.0% of S. Typhi isolates and 0.4% of S. Paratyphi A isolates.
Dr Rastogi Panda warned that every time an antibiotic is misused, it increases the risk of making future infections harder to treat.
She advised people to:
"Cancer patients, ICU patients, the elderly and those with weakened immunity are particularly vulnerable. Responsible antibiotic use, vaccination and good hand hygiene can save lives. Protect antibiotics today, so they protect us tomorrow," the expert said.
Credit: AP Photos
The White House has withdrawn the nomination of physician and presidential adviser Dr. Heidi Overton to lead the Food and Drug Administration (FDA), ending her bid for the top regulatory post just a day before a scheduled Senate committee vote.
Overton, the third reported candidate considered for the position after former FDA Commissioner Marty Makary's departure in May, was nominated by President Donald Trump in August. Trump had praised her as a “ROCKSTAR” when announcing his choice.
“Tonight, the White House abandoned a viable confirmation path for Dr. Overton,” Senate Health, Education, Labor and Pensions Committee Chair Bill Cassidy wrote on X shortly after the withdrawal.
A senior administration official told Axios that Overton “lacks the support on the Hill to move forward with her confirmation.”
Also read: Meet Heidi Overton: Trump Set to Nominate White House Adviser to Lead FDA
The nomination faced growing resistance from Republican members of the 21-member Senate committee. Overton needed the support of all 12 Republicans to advance, assuming all 11 Democrats voted against her.
Several Republican senators had not committed to supporting her, including Cassidy, Susan Collins and Lisa Murkowski. The uncertainty left the White House struggling to secure the votes needed ahead of the November 18 committee hearing.
Cassidy, however, maintained that Overton was close to securing enough support. Calling the withdrawal “odd,” he said he had been having productive conversations with senators and believed she could have cleared both the committee and the full Senate.
Read More: HHS Announces US FDA’s First AI Chief: Here’s What It Means For The Future Of Drug Regulation
Overton faced opposition over her positions on vaccine policy, abortion medication and vaping, exposing divisions among Republicans and the MAHA movement.
Vaccine policy: Cassidy questioned her role in Trump's efforts to change childhood vaccine recommendations, including splitting the combined measles, mumps and rubella (MMR) vaccine. Overton maintained that the MMR vaccine was safe and effective and said she would follow FDA safety requirements.
Mifepristone restrictions: Anti-abortion groups and Republican Sen. Josh Hawley questioned her commitment to tightening restrictions on mifepristone, the abortion pill. Meanwhile, Republican senators Susan Collins and Lisa Murkowski raised concerns about her strong anti-abortion positions.
Flavoured vapes: Overton faced criticism for her role in the administration's authorisation of fruit-flavoured e-cigarettes. Opponents even launched a campaign using the label “Heidi Vaperton” to urge senators to reject her nomination.
MAHA backlash: Some supporters of Robert F. Kennedy Jr.'s Make America Healthy Again movement accused Overton of being too close to corporate and agricultural interests. Former White House adviser Calley Means alleged that her decisions on glyphosate and flavoured vapes conflicted with Kennedy's agenda.
Overton is a physician and former deputy director of the White House Domestic Policy Council. Before her nomination, she worked at the conservative think tank America First Policy Institute, where she eventually led its Health Policy Center.
She received her medical degree from the University of New Mexico, completed general surgery training at Johns Hopkins University and pursued clinical investigation research training at the Johns Hopkins Bloomberg School of Public Health.
She also served during Trump's first administration before joining the think tank.
Overton was involved in several prominent health policy initiatives under the current administration, including efforts to redesign the food pyramid, overhaul childhood vaccine recommendations and negotiate prescription drug pricing deals.
The withdrawal leaves the FDA without a Senate-confirmed commissioner. Acting Commissioner Kyle Diamantas has been leading the agency since Makary resigned in May.
The administration is now considering potential replacements, including Republican Senator Roger Marshall of Kansas, according to Reuters. No new nominee has been formally announced.
Credit: AI image
Amid growing research in vaccination for different cancers, an experimental cancer vaccine cut the risk of death by 41% in patients with acute myeloid leukemia (AML) in a late-stage clinical trial.
Showing promise in treating the aggressive blood cancer, the findings have given hope to patients whose cancer has returned after treatment and those who have limited options.
The vaccine, called galinpepimut-S (GPS), is being developed by US-based pharma company SELLAS Life Sciences. Results from the Phase 3 REGAL trial showed that patients who received the vaccine lived longer than those given the next best available treatment.
Acute myeloid leukemia is an aggressive blood cancer that begins in the bone marrow, the soft tissue inside bones responsible for producing blood cells. It develops when abnormal immature blood cells multiply rapidly and interfere with the production of healthy red blood cells, white blood cells and platelets.
Common symptoms include persistent fatigue, fever, frequent infections, easy bruising, unusual bleeding and breathlessness.
Treatment usually involves chemotherapy, specific medicines in eligible patients and in some cases, stem-cell transplantation. AML can return after treatment, making it difficult to achieve remission.
The trial involved 126 patients who had achieved remission after treatment but were unable to undergo a stem-cell transplant.
According to the findings, the vaccine reduced the risk of death by 41%. Patients receiving GPS had a median overall survival of 24 months, compared to 14.7 months among those receiving standard treatment. The results also showed a hazard ratio of 0.59 and a p-value of 0.035.
SELLAS plans to discuss the findings with the US Food and Drug Administration (FDA), preparing to submit an application for approval in the first half of 2027.
Also read: Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer
Unlike preventive vaccines, GPS is a therapeutic cancer vaccine. It is developed to help immune system identify and destroy residual cancer cells in the body after treatment.
The vaccine targets a protein called Wilms' Tumour 1 (WT1), which is found in more than 95% of people with AML, according to Memorial Sloan Kettering Cancer Center (MSK), where the vaccine was developed.
GPS contains synthetic peptides, which are short chains of amino acids derived from the WT1 protein. These peptides help the immune system to produce specialised T cells that recognise and attack cancer cells carrying WT1.
In simple terms, the vaccine trains the immune system to identify leftover cancer cells that may be too small to detect through routine testing but could eventually cause cancer recurrence.
Unlike personalised cancer vaccines that are manufactured using an individual patient's tumour, GPS is an off-the-shelf vaccine that can be used in multiple patients.
GPS was generally tolerated well in the Phase 3 trial as no safety concerns were identified. Most side effects were mild to moderate. Reactions at injection sites were among the most commonly reported side effects.
The company, however, has only announced topline results. The detailed findings from the trial's secondary endpoints related to relapse-free and leukemia-free survival, will be presented at a future medical conference.
If the findings are supported by regulatory authorities, GPS could become a new treatment option for patients whose AML has relapsed and those who cannot opt for a stem-cell transplant.
© $2026 Times Horizon Private Limited